CIK 0001783328
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
TScan Therapeutics, Inc.
Sign in to watch- Ticker
- TCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825282075
- Phone
- +1 857-399-9500
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-30 | Nicholson Garry A Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2025-06-30 | Woods Keith Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2025-06-30 | Dorton Katina Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2025-06-30 | Gruia Gabriela Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2025-05-20 | Lynx1 Capital Management LP 10% owner | Purchase | +1,200,000 | $1.20 | $1.4M | 7,946,141 |
| 2025-05-19 | Lynx1 Capital Management LP 10% owner | Purchase | +1,388,794 | $1.20 | $1.7M | 6,746,141 |
| 2025-01-03 | ZDRAVESKI ZORAN See Remarks | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2025-01-03 | MacBeath Gavin Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +800,000 | 800,000 | ||
| 2025-01-03 | Amello Jason Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +270,000 | 270,000 | ||
| 2025-01-03 | Louis Chrystal Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2024-12-26 | Lynx1 Capital Management LP 10% owner | Purchase · Pre-funded Warrant (right to buy) | +7,500,000 | $4.00 | $30.0M | 7,500,000 |
| 2024-12-13 | Lynx1 Capital Management LP 10% owner | Purchase | +100,000 | $2.90 | $290K | 5,357,347 |
| 2024-12-12 | Lynx1 Capital Management LP 10% owner | Purchase | +31,800 | $3.01 | $96K | 5,257,347 |
| 2024-11-15 | Lynx1 Capital Management LP 10% owner | Purchase | +947 | $4.34 | $4K | 5,225,547 |
| 2024-09-23 | Klencke Barbara Director | Purchase | +5,000 | $5.29 | $26K | 45,000 |
| 2024-08-26 | Klencke Barbara Director | Purchase | +5,000 | $5.53 | $28K | 40,000 |
| 2024-08-23 | Klencke Barbara Director | Purchase | +5,000 | $5.69 | $28K | 35,000 |
| 2024-08-23 | ZDRAVESKI ZORAN See Remarks | Option exercise | +54,895 | $4.85 | $266K | 67,111 |
| 2024-08-23 | ZDRAVESKI ZORAN See Remarks | Option exercise | +25,000 | $3.27 | $82K | 92,111 |
| 2024-08-23 | ZDRAVESKI ZORAN See Remarks | Option exercise | +13,125 | $1.81 | $24K | 105,236 |
Page 2 of 8 · 144 trades